Incuron   Report issue

For profit Phase 1 Phase 2
Founded: Moscow Russian Federation (2009)

Organization Overview

First Clinical Trial
2013
NCT01905228
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Incuron | Incuron LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

cbl0137 (5 trials)

Drugs in Phase 1 Trials (2)

ipilimumab (yervoy) (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 1)

Melanoma (Phase 1)

Neoplasms (Phase 1)

Sarcoma (Phase 1)

Skin Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3